Clinical trials: Immunodeficiency
Hiv, HIV Testing
Experiential HIV Testing Increasing Testing Related Knowledge and Practice, and Reduce Stigma Toward HIV of Nurses.
This is a randomized controlled trial design. The investigators plan to recruit about 60 to 70 emergency department nurses from a medical center in Taipei, Taiwan.
- Trial name
- NCT05615935
- Testing
- Experiential HIV Testing
- Where
- Taiwan
- Volunteers
- 74 people
- Sponsor
- National Taiwan University
Diarrhoea
Causes of Rotavirus Vaccine Failure in Zambian Children
Zambia recently introduced routine infant immunization against rotavirus - the most important cause of severe gastroenteritis and diarrhoea mortality in children.
- Trial name
- NCT01886833
- Where
- Zambia
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Opioid-use Disorder, Adherence, Medication
Social Networks and Methadone Maintenance Treatment Retention and Antiretroviral Therapy Retention in Tanzania
Investigators will adapt the Brief Social Behaviour and Network Therapy (B-SBNT) intervention developed to facilitate recovery among people receiving medication-assisted treatment for opioid use disorder in the United Kingdom.
- Conditions
- Opioid-use Disorder, Adherence, Medication, HIV Infections
- Trial name
- NCT04479475
- Testing
- Supportive care through community support persons
- Where
- Tanzania
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Dementia
Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)
HIV associated neurological disorders (HAND), are a major problem even in ART treated people. HAND results from chronic inflammation which is largely attributed to expansion and activation of monocytes.
- Trial name
- NCT01600170
- Testing
- Atorvastatin (generic Lipitor)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Pennsylvania
HIV Infections
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- MOTIVATE 2 (NCT00098722)
- Testing
- Maraviroc (UK-427,857), optimized background therapy
- Where
- 172 sites in United States, Australia and 11 more
- Volunteers
- 474 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Viruses
Evaluation of Diagnostic HIV Ag/Ab Combo Assay
To test blood specimens using a new investigational test that detects antigen and antibody to human immunodeficiency virus (HIV).
- Trial name
- NCT00933933
- Testing
- ARCHITECT HIV Ag/Ab Combo
- Where
- 13 sites in United States
- Volunteers
- 635 people, healthy volunteers welcome
- Sponsor
- Abbott Diagnostics Division
Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG
Non-Interventional Study on the Tolerability and Efficacy of IVIG
Non-Interventional Study on the Tolerability and Efficacy of octagam® 10%
- Trial name
- GAM 10-06 (NCT02303093)
- Testing
- Octagam IVIG 5% or 10%, Panzyga
- Where
- 38 sites in Austria, Canada and 3 more
- Volunteers
- 344 people
- Sponsor
- Octapharma
HIV Infections, Depression
Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
The primary purpose of this study was to test the whether high-risk, HIV-seronegative persons with mild-to-moderate depression would be more likely to adopt protective behavior change when provided with pharmacotherapy for their…
- Trial name
- NCT00285584
- Testing
- Bupropion
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- NYU Langone Health
Human Immunodeficiency Virus
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
The purpose of this study is to determine whether an intervention (CARE+ Corrections) delivered to HIV-infected detainees within the DC Department of Corrections (DOC) and recently -released ex-detainees in the community can…
- Trial name
- CARE+ (NCT01721226)
- Testing
- Intervention Arm (computer-based CARE+ Corrections tool), Educational video on opiate overdose prevention
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- George Washington University
Pain
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
The primary aim of this study is to determine if chronic pain subjects on around-the-clock opioids who are receiving 100 to 220 mg oral morphine sulfate equivalent (MSE) can be safely transitioned on to buprenorphine…
- Trial name
- NCT01871285
- Testing
- Buprenorphine, Oxycodone, Morphine sulfate
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- BioDelivery Sciences International
Thrombocytopenia, Hepatitis C
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Thrombocytopenia occurs when a person's blood has a decreased number of platelets, which are cells involved in blood clotting. This condition may lead to uncontrolled bleeding and can be fatal.
- Conditions
- Thrombocytopenia, Hepatitis C, HIV Infections
- Trial name
- NCT00239733
- Testing
- Anti-D
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus, HIV Infections
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected antiretroviral experienced, integrase-naïve…
- Trial name
- SAILING (NCT01231516)
- Testing
- GSK1349572, Raltegravir
- Where
- 180 sites in United States, Argentina and 18 more
- Volunteers
- 724 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis B
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
The primary objective of this study is to evaluate hepatitis B surface antigen (HBsAg) loss and seroconversion in participants who stop tenofovir disoproxil fumarate (TDF) (Stop TDF arm) compared to participants who continue TDF…
- Trial name
- FINITE CHB (NCT01320943)
- Testing
- TDF, Stop TDF
- Where
- 13 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Gilead Sciences
Hiv, Opioid-use Disorder
Integrating Addiction Treatment and HIV Services Into Primary Care Clinics in Ukraine
A randomized controlled trial to: 1. To compare both primary (composite quality health indicator (QHI) scores) and secondary (individual HIV/methadone maintenance treatment (MMT)/TB/primary care QHI scores, quality of life, and…
- Trial name
- IMPACT (NCT04927091)
- Testing
- Integration of HIV and PWID services
- Where
- Ukraine
- Volunteers
- 1,590 people
- Sponsor
- Yale University
Infection, Human Immunodeficiency Virus
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
The purpose of this randomized, double-blinded study is to test the safety of GSK1265744 and how well it works on reducing the amount of HIV in the blood.
- Trial name
- NCT00920426
- Testing
- GSK1265744 30mg, GSK1265744 5mg
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- ViiV Healthcare
HIV Infections, Contraception
Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa
The study investigators are conducting an observational, parallel group pharmacokinetic (PK) study among women living with HIV (WLHIV) already on 1st line antiretroviral therapy (ART) and virally suppressed, 18-45 years old…
- Conditions
- HIV Infections, Contraception, Drug-drug Interaction
- Trial name
- EPIC (NCT04669678)
- Testing
- Etonogestrel (ETG) implant, Intramuscular depo-medroxyprogesterone acetate (IM DMPA), Sub-cutaneous medroxyprogesterone acetate (SC MPA)
- Where
- South Africa
- Volunteers
- 110 people
- Sponsor
- University of Alabama at Birmingham
HIV/AIDS, Cocaine Use
Project SMART Automated Pillbox Study
The aim of this study is to examine the effect of mHealth tools on antiretroviral (ART) adherence and persistence among HIV-infected individuals with co-occurring cocaine use disorders (CUDs).
- Trial name
- SMART (NCT04418076)
- Testing
- Group A_No feedback, Group B_Automated feedback, Group C_Automated feedback + Clinician feedback
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Yale University
HIV Infection, Hepatitis B
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
The purpose of this study was to evaluate response to and safety of the HBV vaccine HEPLISAV-B in two study populations of people living with HIV: prior HBV vaccine recipients who are deemed non-responders and individuals who are…
- Trial name
- BEe-HIVe (NCT04193189)
- Testing
- HEPLISAV-B, ENGERIX-B
- Where
- 41 sites in United States, Botswana and 8 more
- Volunteers
- 638 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Risk Behavior, HIV/AIDS
Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs
This study will evaluate the efficacy and cost-effectiveness of CHRP-BB - an integrated bio-behavioral approach that incorporates the use of PrEP - with an evidence-based behavioral approach aimed at enhancing PrEP adherence and…
- Conditions
- Risk Behavior, HIV/AIDS, Medication Adherence, Substance Abuse
- Trial name
- CHRP-BB (NCT03282890)
- Testing
- CHRP-BB
- Where
- United States
- Volunteers
- 237 people
- Sponsor
- University of Connecticut
Primary Immunodeficiency
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
This study was designed to determine a dose of weekly subcutaneously administered Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols) (IGSC 20%) that produces steady-state AUC of total IgG that…
- Trial name
- NCT02604810
- Testing
- IGIV-C 10%, IGSC 20%
- Where
- 25 sites in United States, Canada
- Volunteers
- 53 people
- Sponsor
- Grifols Therapeutics LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.